Boolean-network learning prioritizes an IBD organoid barrier target
Learning from transcriptomic networks helped prioritize PRKAB1 for experimental follow-up. An agonist improved a barrier-resistance endpoint in about 80% of diseased patient-derived organoids in the tested sample. This is preclinical target-response evidence, not treatment of patients or clinical efficacy. The network direction incorporates sample labels and does not independently establish causal disease progression.
Technology: Boolean Network Explorer learned implication networks
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Patient-derived organoid barriers and preclinical models were tested.
- Still unknown: Clinical safety and benefit, independent replication and causal network direction remain unestablished.
- AI role: Boolean Network Explorer learned implication networks supported the stated study; experimental and interpretive work remained with researchers.
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC8275683/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review date: 16 Nov 2026. Review scope: Primary article metadata, affiliations, selected network Methods and organoid Results; supplements not reviewed..
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.